Quick Answer
Lyell Immunopharma, Inc. reported Net Income of -$274.45 million for fiscal year 2025.
Lyell Immunopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$274.45M | +20.0% |
| 2024 | -$342.99M | -46.2% |
| 2023 | -$234.63M | -28.1% |
| 2022 | -$183.12M | +26.8% |
| 2021 | -$250.22M | -22.4% |
| 2020 | -$204.47M | -58.0% |
| 2019 | -$129.38M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$38.85M | +12.9% | +9.0% |
| June 30, 2025 | -$42.68M | +6.8% | +18.2% |
| March 31, 2025 | -$52.20M | +14.0% | -17.1% |
| September 30, 2024 | -$44.58M | +12.3% | +2.7% |
| June 30, 2024 | -$45.81M | +28.3% | +24.5% |
| March 31, 2024 | -$60.67M | +9.4% | -19.3% |
| September 30, 2023 | -$50.85M | +27.6% | +20.4% |
| June 30, 2023 | -$63.89M | -75.9% | +4.6% |
- Lyell Immunopharma, Inc. showed an increase of +20.0% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Lyell Immunopharma, Inc.’s net income has declined by 112.1% (from -$129.38 million to -$274.45 million).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: